Literature DB >> 11822811

Ivermectin toxicity in 17 collies.

Kate Hopper1, Janet Aldrich, Steve C Haskins.   

Abstract

Ivermectin is widely used in veterinary medicine as an anthelminthic and generally has a wide margin of safety, but Collies are prone to ivermectin toxicity. Two groups of Collies were presented to the University of California Veterinary Medical Teaching Hospital (VMTH) with ivermectin toxicity. The medical records of the 2 groups of Collies were reviewed retrospectively. Group I comprised 5 adult Collies that received at least 400 microg/kg ivermectin p.o. and were presented to the VMTH 3 hours after intoxication. These Collies showed marked clinical signs on presentation. Three of these dogs required mechanical ventilation and were euthanized for financial reasons; the remaining 2 dogs were comatose but recovered in 5-7 days. Group II was comprised of 12 adult Collies presented to the VMTH 2 days (n = 10) and 5 days (n = 2) after subcutaneous injection of 200-250 microg/kg ivermectin. These animals showed greater variation in severity of illness among individuals; 5 animals progressed to stupor or coma, whereas 4 animals remained ambulatory. Most of these dogs' clinical signs deteriorated from the day of intoxication until approximately day 6, from which time they showed gradual but steady improvement. All of the Collies in this group survived, but it took 3 weeks for most of them to recover. Collies suffering from ivermectin toxicity can have a severe and prolonged clinical course requiring intensive nursing care. Respiratory, cardiovascular, and nutritional support may all be required. With appropriate care, however, the prognosis for complete recovery is good.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11822811     DOI: 10.1892/0891-6640(2002)016<0089:itic>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  13 in total

Review 1.  Control of nematode parasites with agents acting on neuro-musculature systems: lessons for neuropeptide ligand discovery.

Authors:  Richard J Martin; Alan P Robertson
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

2.  Ivermectin activates GIRK channels in a PIP2 -dependent, Gβγ -independent manner and an amino acid residue at the slide helix governs the activation.

Authors:  I-Shan Chen; Michihiro Tateyama; Yuko Fukata; Motonari Uesugi; Yoshihiro Kubo
Journal:  J Physiol       Date:  2017-07-30       Impact factor: 5.182

Review 3.  Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats.

Authors:  Valentina M Merola; Paul A Eubig
Journal:  Vet Clin North Am Small Anim Pract       Date:  2012-03       Impact factor: 2.093

4.  Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers.

Authors:  David J Brayden; Joanna Griffin
Journal:  Vet Res Commun       Date:  2007-06-20       Impact factor: 2.459

5.  Histopathology of the tegument of rabbits infested by Rhipicephalus sanguineus (ACARI: IXODIDAE) ticks and exposed to selamectin (active principle of acaricide Revolution, Pfizer).

Authors:  Vlamir Bozzatto; Patrícia Rosa de Oliveira; Maria Izabel Camargo-Mathias
Journal:  Parasitol Res       Date:  2013-04-24       Impact factor: 2.289

6.  Efficacy of selamectin in the treatment of naturally acquired cheyletiellosis in cats.

Authors:  Nadège Chailleux; Manon Paradis
Journal:  Can Vet J       Date:  2002-10       Impact factor: 1.008

Review 7.  Moxidectin and the avermectins: Consanguinity but not identity.

Authors:  Roger Prichard; Cécile Ménez; Anne Lespine
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-14       Impact factor: 4.077

Review 8.  Treatment of MDR1 mutant dogs with macrocyclic lactones.

Authors:  Joachim Geyer; Christina Janko
Journal:  Curr Pharm Biotechnol       Date:  2012-05       Impact factor: 2.837

9.  Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

Authors:  Charles D Mackenzie; Timothy G Geary; John A Gerlach
Journal:  Filaria J       Date:  2003-10-24

10.  Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.

Authors:  Cécile Ménez; Jean-François Sutra; Roger Prichard; Anne Lespine
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.